Nanion Corporate Blog


29.08.2019: Pushing the boundaries of hiPSC-CMs in cardiac safety

The new FLEXcyte 96 system for in vitro cardiac contractility measurements is addressing the demands for both physiological relevance and throughput.

We are proud to announce that the platform will be available as of September 16th, 2019!

Read the Whitepaper and learn about iPSC-CM maturity, reference compound effects and where the FLEXcyte 96 technology can be positioned in your drug discovery project.

For FLEXcyte 96 screening services kindly visit innoVitro's official website, for orders, updates and more information on the system please see

Back to Overview

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok